candesartan has been researched along with Hepatocellular Carcinoma in 2 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candesartan was able to reverse this process in a dose-dependent manner." | 5.43 | Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway. ( Fan, F; Jiang, G; Liu, Z; Lu, Y; Shen, C; Tao, L; Tian, C; Wu, H, 2016) |
| "Candesartan was able to reverse this process in a dose-dependent manner." | 1.43 | Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway. ( Fan, F; Jiang, G; Liu, Z; Lu, Y; Shen, C; Tao, L; Tian, C; Wu, H, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, F | 1 |
| Tian, C | 1 |
| Tao, L | 1 |
| Wu, H | 1 |
| Liu, Z | 1 |
| Shen, C | 1 |
| Jiang, G | 1 |
| Lu, Y | 1 |
| Cook, JL | 1 |
| Zhang, Z | 1 |
| Re, RN | 1 |
2 other studies available for candesartan and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway.
Topics: Angiogenesis Inhibitors; Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Carcinoma, Hep | 2016 |
In vitro evidence for an intracellular site of angiotensin action.
Topics: Alternative Splicing; Angiotensin Receptor Antagonists; Angiotensinogen; Angiotensins; Animals; Anti | 2001 |